Trial Profile

Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Trametinib (Primary)
Indications Cholangiocarcinoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
Focus Adverse reactions; Therapeutic Use

11 Jun 2019 The thyroid cancer cohort was terminated after planned interim analysis suggested insufficiently increased activity against the historical control of pazopanib alone, according to the results published in the Clinical Cancer Research.
11 Jun 2019 Safety and efficacy results from thyroid cancer cohort (n=26) published in the Clinical Cancer Research.
28 Aug 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com